Retired investment banker, private investor and executive (C-level) consultant. Investing/trading since 1981
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry but no pinks or OTCBBs on this board…
Sorry but no pinks or OTCBBs on this board…
Another buy of 20,000 at the .044 offer and the 71,000 size still the same…
Lasted twenty seconds, felt like the roof was gonna crack…
4.8 magnitude in central NJ…
FLGC Cannabis exploding on AH
Come on, stop the nonsense pumps, geez…
Sorry but no pinks or OTCBBs on this board…
I see trades being bought at the .044 offer the last several days and the 71,000 size hasn’t changed, I wonder how much is really there?
Been doing bear credit spreads on the calls, easy money…
Now that the fins are updated, the first quarter and attorney letter should be out shortly imo and the yield sign removed, just my guesstimate…
GREENSHIFT CORPORATION
(N/K/A CLEANTECH ALPHA CORPORATION)
1800 NE 135th Street Oklahoma City, OK 73131
1-888-510-2392
www.greenshift.com
info@greenshift.com
Annual Report
For the period ending December 31, 2023 (the “Reporting Period”)
https://www.otcmarkets.com/otcapi/company/financial-report/396110/content
Updated fins posted 3/31/24…
https://www.otcmarkets.com/stock/GERS/disclosure
Sorry but no pinks or OTCBBs on this board…
Finviz is wrong, SXTC doesn’t have $30/share cash, read this, especially page 6…
https://www.sec.gov/Archives/edgar/data/1723980/000121390023061294/f20f2023_chinasxtphar.htm
We have limited sources of working capital and will need substantial additional financing
The working capital required to implement our business plan will most likely be provided by funds obtained through offerings of our equity, debt, debt-linked securities, and/or equity-linked securities, and revenues generated by us. No assurance can be given that we will have revenues sufficient to sustain our operations or that we would be able to obtain equity/debt financing in the current economic environment. If we do not have sufficient working capital and are unable to generate sufficient revenues or raise additional funds, we may delay the completion of or significantly reduce the scope of our current business plan; delay some of our development and clinical or marketing efforts; postpone the hiring of new personnel; or, under certain dire financial circumstances, substantially curtail or cease our operations.
To date, we have relied almost exclusively on organically generated revenues and financing transactions to fund our operations. Our inability to obtain sufficient additional financing would have a material adverse effect on our ability to implement our business plan and, as a result, could require us to significantly curtail or potentially cease our operations. As of March 31, 2023, we had cash and cash equivalents and restricted cash of $17,368,478, total current assets of $19,521,247 and total current liabilities of $14,496,938. As of March 31, 2022, we had cash and cash equivalents of $15,524,322, total current assets of $22,451,855 and total current liabilities of $17,121,565. We will need to engage in capital-raising transactions in the near future. Such financing transactions may well cause substantial dilution to our shareholders and could involve the issuance of securities with rights senior to the outstanding shares. Our ability to complete additional financings is dependent on, among other things, the state of the capital markets at the time of any proposed offering, market reception of the Company and the likelihood of the success of its business model and offering terms. There is no assurance that we will be able to obtain any such additional capital through asset sales, equity or debt financing, or any combination thereof, on satisfactory terms or at all. Additionally, no assurance can be given that any such financing, if obtained, will be adequate to meet our capital needs and to support our operations. If we do not obtain adequate capital on a timely basis and on satisfactory terms, our revenues and operations and the value of our Ordinary Shares and Ordinary Share equivalents would be materially negatively impacted and we may cease our operations.
🔒 Behind Bars, Beyond Germs: Hydrolyte® has a Vital Role in Prison Hygiene! 🔒
Incarceration facilities demand top-notch hygiene solutions, and Hydrolyte® rises to the challenge! With its powerful disinfectant properties, Hydrolyte® plays a crucial role in maintaining cleanliness and safety behind bars.
💪 Why Hydrolyte® is Essential for Prison Hygiene:
🚨 Effectively kills germs, bacteria, and viruses
🔒 Harmless to use around inmates and staff
👌 Easy to use, with versatile application options
🌿 Environmentally friendly and sustainable
Upgrade your prison hygiene protocols with Hydrolyte® and ensure a healthier environment for all.
#HydrolyteHeroes #PrisonHygiene #CleanAndSafe 🛡️🧼
Oh boy, another one!!
🔒 Behind Bars, Beyond Germs: Hydrolyte® has a Vital Role in Prison Hygiene! 🔒
— PCTL (@PCTL_) April 1, 2024
Incarceration facilities demand top-notch hygiene solutions, and Hydrolyte® rises to the challenge! With its powerful disinfectant properties, Hydrolyte® plays a crucial role in maintaining… pic.twitter.com/tlinEYgBX7
Elevate your expectations with PCT's Premier Hypochlorous Acid Product, Hydrolyte®!
Experience the power of cleanliness like never before! Hydrolyte® solution from PCT is here to revolutionize your sanitization routine. Say goodbye to harmful germs and hello to a safer, healthier environment.
Why choose Hydrolyte®?
* Effective against a wide range of bacteria and viruses
* Eco-friendly and safe for everyday use
* Versatile application: use it on surfaces and more
*Odorless and gentle, suitable for all environments
Upgrade your cleaning game today and discover the difference with PCT's Hydrolyte®! #CleanLiving #HealthyHomes #PCTInnovations 🌿💧
Oh lookie here, another goodie!!
Elevate your expectations with PCT's Premier Hypochlorous Acid Product, Hydrolyte®!
— PCTL (@PCTL_) April 1, 2024
Experience the power of cleanliness like never before! Hydrolyte® solution from PCT is here to revolutionize your sanitization routine. Say goodbye to harmful germs and hello to a safer,… pic.twitter.com/HKA2Xd26DR
If you don’t get an answer to your email then that will be your answer, if you know what I mean…
PROSPECTUS SUPPLEMENT
(To Prospectus dated March 31, 2022)
VERB TECHNOLOGY COMPANY, INC.
Up to $960,000
COMMON STOCK
We have entered into an ATM Sales Agreement (the “Sales Agreement”), with Ascendiant Capital Markets, LLC (the “Sales Agent” or “ACM”) relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $960,000 from time to time through or to ACM, acting as our agent or principal.
Our common stock is listed on The Nasdaq Capital Market under the symbol “VERB.” The aggregate market value of our outstanding common stock held by non-affiliates is approximately $10,740,562 based on 19,332,657 shares of outstanding common stock, of which 221,336 shares are held by affiliates, and a per share price of $0.5620, which was the closing sale price of our common stock as quoted on The Nasdaq Capital Market on October 17, 2023. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement of which this prospectus supplement is a part with a value of more than one-third of the aggregate market value of our common stock held by non-affiliates in any 12-month period, so long as the aggregate market value of our common stock held by non-affiliates is less than $75,000,000. During the 12 calendar month period that ends on, and includes, the date of this prospectus supplement, we sold $2,618,136 shares pursuant to General Instruction I.B.6 of Form S-3.
Sales of our common stock, if any, under this prospectus supplement will be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. ACM is not required to sell any specific amount of securities but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between ACM and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
The compensation to ACM for sales of common stock sold pursuant to the Sales Agreement will be up to 3% of the gross proceeds of any shares of common stock sold under the Sales Agreement. In connection with the sale of the common stock on our behalf, ACM will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of ACM will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to ACM with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.
Investing in our securities involves a high degree of risk. Before buying any of our securities, you should carefully consider the risk factors described in “Risk Factors” on page 7 of this prospectus supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
SUPPLEMENT NO.2 TO
PROSPECTUS SUPPLEMENT DATED DECEMBER 15, 2023
(To Prospectus dated March 31, 2022)
VERB TECHNOLOGY COMPANY, INC.
Up to $9,010,000
COMMON STOCK
This prospectus supplement supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our prospectus supplement dated December 15, 2023, as supplemented by the supplement to the prospectus supplement dated March 19, 2024, which together with the accompanying prospectus dated March 31, 2022 contained in our Registration Statement on Form S-3 (Registration No. 333-264038), we refer to as the prospectus, relating to the issuance and sale of shares of our common stock, par value $0.0001 per share, from time to time through our sales agent, Ascendiant Capital Markets, LLC, or ACM. These sales, if any, will be made pursuant to the terms of the At-The-Market Issuance Sales Agreement, or the Sales Agreement, we entered into with ACM.
This prospectus supplement should be read in conjunction with, is not complete without, and may not be delivered or utilized except in connection with, the prospectus, including all supplements thereto and documents incorporated by reference therein. If there is any inconsistency between the information in the prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. Any information that is modified or superseded in the prospectus shall not be deemed to constitute a part of the prospectus, except as modified or superseded by this prospectus supplement.
As of March 28, 2024, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was $34,970,071, which was calculated based on 79,082,024 shares of our outstanding common stock held by non-affiliates at a price of $0.4422 per share, the closing price of our common stock on March 15, 2024. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell shares pursuant to this prospectus supplement with a value of more than one-third of the aggregate market value of our common stock held by non-affiliates in any 12-month period, or $11,656,690. As of the date of this prospectus supplement, we have sold $8,876,709 of securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to, and including, the date of this prospectus supplement, and are therefore eligible to sell up to an additional $2,779,981 of our securities pursuant to General Instruction I.B.6 of Form S-3. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than one-third of the aggregate market value of our voting and non-voting common equity held by non-affiliates in any 12-month period so long our public float remains below $75 million.
We are filing this prospectus supplement to supplement and amend, as of March 29, 2024, the prospectus, as supplemented, to increase the maximum aggregate offering price of our common stock that may be offered, issued and sold under the prospectus, as supplemented and amended by this prospectus supplement, pursuant to the Sales Agreement from $6,260,000 to $9,010,000. From and after the date hereof, pursuant to General Instruction I.B.6 of Form S-3, we are offering to issue and sell up to $9,010,000 from time to time through ACM, acting as our sales agent or principal in accordance with the Sales Agreement, as amended.
Our common stock is traded on The Nasdaq Capital Market under the symbol “VERB.” The closing price of our common stock on March 27, 2024 was $0.281 per share.
Sales of our common stock, if any, under this prospectus supplement and accompanying prospectus may be made in sales deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended, or the Securities Act. ACM is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on terms mutually agreed to by ACM and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
The compensation to ACM for sales of common stock sold pursuant to the Sales Agreement will be up to 3% of the gross proceeds of any shares of common stock sold under the Sales Agreement. In connection with the sale of the common stock on our behalf, ACM will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of ACM will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to ACM with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.
Investing in our securities involves a high degree of risk. Before buying any of our securities, you should carefully consider the risk factors described in “Risk Factors” on page S-7 of the prospectus supplement dated December 15, 2023, on page 4 of the prospectus and under similar headings in other documents that are incorporated by reference into this prospectus supplement and the prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
Complete filing: https://www.sec.gov/Archives/edgar/data/1566610/000149315224012023/form424b5.htm
8-K out yesterday…
Item 1.01 Entry into a Material Definitive Agreement.
As previously reported, on December 15, 2023, Verb Technology Company, Inc. (the “Company”) entered into an At-the-Market Issuance Sales Agreement (the “Sales Agreement”) with Ascendiant Capital Markets, LLC, as sales agent (the “Agent”) to sell shares of its common stock, par value $0.0001 (the “Common Stock”), having an aggregate offering price of up to $960,000 (the “Shares”) from time to time, through an “at the market offering” (the “ATM Offering”) as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”). On December 15, 2023, the Company filed a prospectus supplement with the Securities and Exchange Commission (“SEC”) relating to the offer and sale of up to $960,000 of common stock in the ATM Offering (the “Prospectus Supplement”).
As previously reported, on March 19, 2024, the Company entered into the First Amendment to At-The-Market Issuance Sales Agreement, dated March 19, 2024 to increase the number of shares to be sold in the ATM Offering to $6,260,000
On March 29, 2024, the Company entered into the Second Amendment to At-The-Market Issuance Sales Agreement, dated March 29, 2024 (the “Amendment”) to increase the number of shares to be sold in the ATM Offering to $9,010,000
The Company will file a supplement to the Prospectus Supplement (the “Supplement”) with the SEC to increase the amount of Common Stock that may be offered and sold in the ATM Offering under the Sales Agreement to up to $9,010,000 in the aggregate.
This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of any offer to buy any shares under the Sales Agreement, nor shall there be any offer, solicitation or sale of such shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.
The foregoing description of the terms of the Sales Agreement, as amended by the Amendment, does not purport to be complete and is subject to, and qualified in its entirety by reference to, the Amendment, which is filed herewith as Exhibit 10.1 and is incorporated herein by reference.
The legal opinion of Sichenzia Ross Ference Carmel LLP, counsel to the Company, relating to the legality of the issuance and sale of shares of Common Stock being offered pursuant to the Sales Agreement, as amended by the Amendment, is filed as Exhibit 5.1 hereto.
Complete filing: https://www.sec.gov/ix?doc=/Archives/edgar/data/1566610/000149315224012020/form8-k.htm
8-K filing from Wednesday 3/27/24 about TikTok press release…
Item 8.01. Other Events
On March 27, 2024, Verb Technology Company, Inc. issued a press release announcing it has entered into a formal partnership with TikTok Shop pursuant to which MARKET.live has become a service provider for TikTok Shop and is officially designated as a TikTok Shop Partner. Under the terms of the partnership, TikTok Shop refers consumer brands, retailers, influencers and affiliates leads to Market.live for a menu of paid services that include, among other things, assistance in onboarding to TikTok and establishing a TikTok store, hosting training sessions and webinars for prospective TikTok Shop sellers, studio space rental in both the West Coast and East Coast MARKET.live studios, content creation and production services, and TikTok Shop maintenance, including enhancements to existing TikTok Shop seller stores. A copy of the press release is attached hereto as Exhibit 99.1.
Complete filing: https://www.sec.gov/Archives/edgar/data/1566610/000149315224011393/form8-k.htm
I’m not trying to be an ass, trying to be helpful. I had my commodities license for 35+ years…
Happy Easter and enjoy the 3day weekend…
You’re welcome…
NT 10-K (notice it would be filed late, after the deadline) was filed last year on 3/31/23 and 10-K was filed on 4/17/23 so we might see either sometime today or Monday…
Link to all SEC filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001566610&owner=include&count=40&hidefilings=0
A short is a short is a short, doesn’t matter if it’s a stock or commodity and the more the short goes against the shorters the more money they’ll lose…
Not here to argue, believe whatever you want…
Why are you against shorts? They only add fuel to the fire if what they’re short keeps steadily rising and eventually have to cover …
Stop listening to novice traders who don’t know what they’re talking about…
Yes, best time of year for sports, imo…
It’s opening day, my favorite day of the year… 😎🥳
PROSPECTUS SUPPLEMENT
(To Prospectus dated March 28, 2022)
Up to $5,000,000
Common Stock
We have entered into an equity purchase agreement dated March 25, 2024, with ClearThink Capital Partners LLC, or the Investor, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of such agreement, we may offer and sell shares of our common stock with a maximum offering size, in the aggregate, of up to $5,000,000 to the Investor.
Our common stock is listed on the NYSE American under the symbol “LODE.” The last reported sale price of our common stock on the NYSE American on March 25, 2024 was $0.34 per share.
Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, at a discount of 10.0% to the lowest intra-day reported sales price of the common stock on the date that the Investor receives a capital call from the Company.
We estimate that the total gross proceeds from this offering will be approximately $5,000,000. We estimate the total expenses of this offering, excluding the discount to the Investor, will be $15,000. In consideration of the Investor’s agreement to enter the equity purchase agreement, we agreed to deliver 250,000 restricted shares of our common stock with value of $85,000 the Investor, for no additional consideration, on the first settlement date with respect to a put notice delivered by the Company. We also agreed to provide “most favored nation” status to the Investor with respect to other equity offerings conducted within five trading days of a sale under the equity purchase agreement. The Investor may be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation and discounts received by the Investor will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution with respect to certain liabilities, including liabilities under the Securities Act.
Complete filing: https://www.sec.gov/Archives/edgar/data/1120970/000143774924009447/lode20240325_424b5.htm
Item 8.01 Other Events.
On March 25, 2024, Comstock Inc. (the “Company”) entered into an equity purchase agreement (the “Purchase Agreement”) with ClearThink Capital Partners LLC (“ClearThink”) for the offering from time to time of the Company's common shares with a maximum offering size, in the aggregate, of up to $5,000,000 to ClearThink.
Sales of common stock, if any, under the Purchase Agreement are made at a 10% discount lowest intra-day reported sales price of the common stock on the date that ClearThink receives a capital call from the Company. In consideration of ClearThink's agreement to enter the Purchase Agreement, the Company agreed to deliver 250,000 additional shares of common stock to ClearThink, for no additional consideration.
Complete filing: https://www.sec.gov/Archives/edgar/data/1120970/000112097024000021/lode-20240325.htm
🌟 Harnessing the Power of Hypochlorous Acid! 🌟
Prescribing Protection: Dive into the cutting-edge world of hospital hygiene with the incredible potency of Hydrolyte!
From disinfecting surfaces to safeguarding patient health, its effectiveness knows no bounds.
#HealthcareInnovation #StaySafe #HygieneMatters
Keep ‘em coming!!! LOL!!!!!!
🌟 Harnessing the Power of Hypochlorous Acid! 🌟
— PCTL (@PCTL_) March 28, 2024
Prescribing Protection: Dive into the cutting-edge world of hospital hygiene with the incredible potency of Hydrolyte!
From disinfecting surfaces to safeguarding patient health, its effectiveness knows no bounds.… pic.twitter.com/yjtXu4qrtG
Wrong board…
AIRI
Air Industries Group To Preliminary Report Q4 and FY 2023 Results on April 1, 2024 and Schedules Earnings Conference Call
March 27 2024 - 05:06PM
Business Wire
Air Industries Group (NYSE American: AIRI), a leading manufacturer of precision components and assemblies for large aerospace and defense prime contractors, today announced that it plans to release its preliminary Q4 fiscal and full-year 2023 results after the market closes on Monday, April 1, 2024.
Conference Call Information
At 4:30 ET that day, the Company will also host a conference call to discuss its results and 2024 Business Outlook. Individuals can access the call by dialing 877-524-8416. An audio replay of the call will be available on the Company’s investor relations website shortly thereafter.
ABOUT AIR INDUSTRIES GROUP
Air Industries Group is a leading manufacturer of precision components and assemblies for large aerospace and defense prime contractors. Its products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. Whether it is a small individual component or complete assembly, its high quality and extremely reliable products are used in mission critical operations that are essential for the safety of military personnel and civilians.
Savor the clean!!!
Yippee!!!!!
🍴✨ Savor the Clean! 🍽️✨
— PCTL (@PCTL_) March 27, 2024
Introducing a game-changer in restaurant hygiene: Hydrolyte! 🌟 Say goodbye to worries and hello to elevated standards of cleanliness. 😌✨ Shop our products at https://t.co/uRh0Dls09N!#HygieneRevolution #CleanEats #RestaurantSafety 🍲🧼👌 pic.twitter.com/1hW7E5DDHX
Wwhheeee!!!!
📚🍎 Smart Solutions for Safer Schools! Introducing Hydrolyte, our go-to solution for enhancing sanitation in educational facilities.
With its powerful yet gentle formula, we're ensuring a clean and safe environment for students and staff alike.
Let's prioritize health and learning hand in hand! #SchoolSafety #Sanitation
Oh boy, here’s another one, lol!!!
📚🍎 Smart Solutions for Safer Schools! Introducing Hydrolyte, our go-to solution for enhancing sanitation in educational facilities.
— PCTL (@PCTL_) March 26, 2024
With its powerful yet gentle formula, we're ensuring a clean and safe environment for students and staff alike.
Let's prioritize health and… pic.twitter.com/PtMebQiQfM